FIELD: medicine.
SUBSTANCE: invention relates to biotechnology and medicine and can be used in cardiology, angiology, cardiac surgery, therapy, rehabilitology. The concentration of cytomegalovirus DNA per 1 ml of blood plasma is determined by polymerase chain reaction (PCR) with hybridization-fluorescence detection of amplification products in the real-time mode. If the concentration of cytomegalovirus DNA is more than 1418 copies/ml per 1 ml of blood plasma in patients with coronary heart disease, a high risk of developing adverse cardiovascular events is predicted during the next 12 months of follow-up.
EFFECT: proposed method makes it possible to predict the development of adverse cardiovascular events in patients with coronary heart disease during 12 months of follow-up after discharge from the hospital for decompensation of chronic heart insufficiency, which makes it possible to identify a priority group of patients with an increased risk of cardiovascular complications for follow-up monitoring.
1 cl, 1 dwg, 5 tbl, 1 ex
